The prognostic value of IKZF1plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial

Abstract

AbstractBackgroundIKZF1 gene deletion is an indicator of poor prognosis in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). The AEIOP/BFM group proposed that the prognostic strength of IKZF1 deletion could be remarkably improved by taking into account additional genetic deletions and reported that among patients with an IKZF1 deletion those with deletions in CDKN2A/2B, PAX5, or PAR1 in the absence of ERG deletion, grouped as IKZF1plus, had the worst outcome.ProcedureBetween 1998 and 2008, 1636 patients under 18 years of age with previously untreated BCP‐ALL were registered in the EORTC 58951 trial. Those with multiplex ligation‐dependent probe amplification data were included in this analysis. Unadjusted and adjusted Cox model was used to investigate the additional prognostic value of IKZF1plus.ResultsAmong 1200 patients included in the analysis, 1039 (87%) had no IKZF1 deletion (IKZF1WT), 87 (7%) had an IKZF1 deletion but not IKZF1plus (IKZF1del) and 74 (6%) had IKZF1plus. In the unadjusted analysis, both patients with IKZF1del (hazard ratio [HR] = 2.10, 95% confidence interval [CI]: 1.34–3.31) and IKZF1plus (HR = 3.07, 95% CI: 2.01–4.67) had a shorter event‐free survival compared with IKZF1WT. However, although the IKZF1plus status was associated with patients’ characteristics indicating poor prognosis, the difference between IKZF1plus and IKZF1del was not statistically significant (HR = 1.46, 95% CI: 0.83–2.57, p = .19). The results of the adjusted analysis were similar to the unadjusted analysis.ConclusionsIn patients with BCP‐ALL from the EORTC 58951 trial, the improvement of the prognostic importance of IKZF1 by considering IKZF1plus was not statistically significant.